购物车
- 全部删除
- 您的购物车当前为空
AGI-5198 (IDH-C35) 是一种选择性的突变体 IDH1R132H 抑制剂,IC50=0.07 μM。
为众多的药物研发团队赋能,
让新药发现更简单!
AGI-5198 (IDH-C35) 是一种选择性的突变体 IDH1R132H 抑制剂,IC50=0.07 μM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | ¥ 178 | 现货 | |
10 mg | ¥ 296 | 现货 | |
25 mg | ¥ 368 | 现货 | |
50 mg | ¥ 436 | 现货 | |
100 mg | ¥ 713 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 325 | 现货 |
产品描述 | AGI-5198 (IDH-C35) is a potent and selective inhibitor of IDH1 R132H and R132C mutants, with IC50 values of 0.07 μM and 0.16 μM, respectively. |
靶点活性 | R132C-IDH1:0.16 μM, R132H-IDH1:70 nM |
体外活性 | 在带有Ki-67蛋白抗体染色的小鼠体内,AGI-5198可使其肿瘤减少.但空白对照组和AGI-5198处理组的小鼠肿瘤中裂解的caspase-3无显著差异.AGI-5198(450 mg/kg/day)治疗R132H-IDH1胶质瘤移植瘤三周,可抑制50-60%的生长,但不影响IDH1野生型胶质瘤移植瘤的生长. |
体内活性 | AGI-5198对TS603胶质瘤细胞系有一定抗肿瘤疗效,且剂量依赖性抑制R-2HG产生。在R-2HG几乎被完全抑制的条件下,AGI-5198对组蛋白H3K9me3去甲基化有诱导作用,且诱导与胶质基因分化相关的基因表达。在全基因组DNA甲基化中,AGI-5198对mIDH1受损的IDH1突变型生长具有抑制作用,但野生型生长几乎没有受到影响。AGI-5198对突变型IDH1(R132H-IDH1 和 R132C-IDH1)有明显抑制作用,但对野生型IDH1 (IC50>100 μM) 或任何IDH2亚型(R140Q, R172K, 野生型) (IC50>100 μM)抑制作用非常弱。 |
激酶实验 | IDH enzyme activity: Compound is prepared as 10 mM stock in DMSO and diluted to 50X final concentration in DMSO, for a 50 μL reaction mixture. IDH enzyme activity converting alpha-ketogluta rate to 2-hydroxyglutarate is measured using a NADPH depletion assay. In the assay the remaining cofactor is measured at the end of the reaction with the addition of a catalytic excess of diaphorase and resazurin, to generate a fluorescent signal in proportion to the amount of NADPH remaining. IDH enzyme activity in the direction of isocitrate to alpha-ketoglutarate conversion is measured by direct coupling of the NADPH production to conversion of resazurin to resorufin by diaphorase. In both cases, resorufin is measured fluorometrically at Ex544 Em 590. |
细胞实验 | AGI-5198 is dissolved in DMSO.TS603 cells are grown in medium containing either AGI-5198 (1.5 μM) or DMSO vehicle control.One week prior to harvest cells are ransferred to differentiation medium (DMEM F12; 15 mM HEPES; 0.06% glucose; B27 without vitamin A; N2; Insulin/transferrin; 1% FBS) containing freshly added retinoic acid (1 μM).ChIP of non-crosslinked cells is then carried out using established ChIP methods.350 μg of lysate is immunoprecipitated-using anti-H3K9Me3,H3K27me3 or Rabbit Control IgG.After washing,ChIP DNA is eluted from protein G beads and analyzed by RT-PCR using SYBR green.Relative occupancy is calculated using the standard curve method and fold enrichment versus IgG.Enrichment in AGI- 5198-treated cells is normalized to vehicle control.Means and standard deviation are calculated from 4 technical replicates. |
别名 | IDH-C35 |
分子量 | 462.56 |
分子式 | C27H31FN4O2 |
CAS No. | 1355326-35-0 |
Smiles | Cc1nccn1CC(=O)N(C(C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1 |
密度 | 1.21 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
溶解度信息 | DMSO: 23 mg/mL (49.7 mM) Ethanol: 12 mg/mL (25.9 mM) H2O: < 1 mg/mL (insoluble or slightly soluble) | |||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||
Ethanol/DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容